On October 11, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc (MYGN, Financial), executed a sale of 15,000 shares of the company. According to the SEC Filing, the transaction occurred at a stock price of $22.93 per share. Following this transaction, the insider now owns 962,378 shares of Myriad Genetics Inc.
Myriad Genetics Inc, a company specializing in molecular diagnostics and personalized medicine, is known for its development of predictive medicine, personalized medicine, and prognostic medicine tests. The company's tests are designed to assess an individual's risk of developing a disease, guide treatment decisions, and assess risk of disease progression and recurrence.
Over the past year, Paul Diaz has sold a total of 257,844 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend seen within the company, where there have been 12 insider sells and no insider buys over the same timeframe.
Shares of Myriad Genetics Inc were trading at $22.93 on the day of the sale, giving the company a market cap of approximately $2.19 billion. According to the GF Value, the intrinsic value of the stock is estimated at $23.50, indicating that the stock is Fairly Valued with a price-to-GF-Value ratio of 0.98.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on the company's past performance and estimated future business outcomes provided by Morningstar analysts.
This insider sale might be of interest to current and potential investors as they evaluate their positions in Myriad Genetics Inc, considering the company's valuation and the insider's ongoing transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
